{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:07:31Z","timestamp":1789153651915,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"DOI":"10.7759\/cureus.116108","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:21:02Z","timestamp":1789150862000},"source":"Crossref","is-referenced-by-count":0,"title":["Systematic Review and Meta-Analysis on Central and\/or Peripheral Nervous System Demyelination in Patients Treated With Tumor Necrosis Factor Alpha (TNF-\u03b1) Inhibitors"],"prefix":"10.7759","author":[{"given":"Shamma","family":"Al Nokhatha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamda","family":"Kamalboor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1003270","article-title":"Drug-related immune-mediated myelopathies","volume":"13","author":"Gritsch D","year":"2022","unstructured":"Gritsch D, Valencia-Sanchez C. Drug-related immune-mediated myelopathies. Front Neurol. 2022, 13:1003270. 10.3389\/fneur.2022.1003270","journal-title":"Front Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081122","article-title":"Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire","volume":"36","author":"Barra L","year":"2009","unstructured":"Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. J Rheumatol. 2009, 36:1421-8. 10.3899\/jrheum.081122","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200301","article-title":"Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events","volume":"22","author":"Murdaca G","year":"2009","unstructured":"Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009, 22:557-65. 10.1177\/039463200902200301","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(24)00128-0","article-title":"Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case-control study","volume":"6","author":"Nakafero G","year":"2024","unstructured":"Nakafero G, Grainge MJ, Card T, Mallen CD, Van-Tam JSN, Abhishek A. Effectiveness of pneumococcal vaccination in adults with common immune-mediated inflammatory diseases in the UK: a case-control study. Lancet Rheumatol. 2024, 6:e615-24.","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05136-x","article-title":"The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era","volume":"42","author":"Evangelatos G","year":"2022","unstructured":"Evangelatos G, Bamias G, Kitas GD, Kollias G, Sfikakis PP. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. Rheumatol Int. 2022, 42:1493-511. 10.1007\/s00296-022-05136-x","journal-title":"Rheumatol Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.075861","article-title":"Demyelination in rheumatic diseases","volume":"77","author":"Theodoridou A","year":"2006","unstructured":"Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry. 2006, 77:290-5. 10.1136\/jnnp.2005.075861","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577525","article-title":"Defining the disease course of TNF\u03b1 blockers-associated multiple sclerosis","volume":"353","author":"Lucchini M","year":"2021","unstructured":"Lucchini M, Giuffr\u00e8 GM, Nociti V, et al.. Defining the disease course of TNF\u03b1 blockers-associated multiple sclerosis. J Neuroimmunol. 2021, 353:577525. 10.1016\/j.jneuroim.2021.577525","journal-title":"J Neuroimmunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou E","year":"2017","unstructured":"Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-\u03b1 blockers. Curr Neurol Neurosci Rep. 2017, 17:36. 10.1007\/s11910-017-0742-1","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/0115748863274863231222023853","article-title":"Tumor necrosis alpha (TNF-\u03b1) antagonists used in chronic inflammatory rheumatic diseases: risks and their minimization measures","volume":"19","author":"Lakhmiri R","year":"2024","unstructured":"Lakhmiri R, Cherrah Y, Serragui S. Tumor necrosis alpha (TNF-\u03b1) antagonists used in chronic inflammatory rheumatic diseases: risks and their minimization measures. Curr Drug Saf. 2024, 19:431-43. 10.2174\/0115748863274863231222023853","journal-title":"Curr Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211070750","article-title":"Central nervous system demyelination related to tumour necrosis factor alpha inhibitor","volume":"8","author":"Chey SY","year":"2022","unstructured":"Chey SY, Kermode AG. Central nervous system demyelination related to tumour necrosis factor alpha inhibitor. Mult Scler J Exp Transl Clin. 2022, 8:20552173211070750. 10.1177\/20552173211070750","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00104","article-title":"Anti-TNF drugs for chronic uveitis in adults\u2014a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Leal I","year":"2019","unstructured":"Leal I, Rodrigues FB, Sousa DC, et al.. Anti-TNF drugs for chronic uveitis in adults\u2014a systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2019, 6:104. 10.3389\/fmed.2019.00104","journal-title":"Front Med (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.889613","article-title":"Demyelinating syndromes in systemic lupus erythematosus: data from the \"Attikon\" Lupus Cohort","volume":"13","author":"Nikolopoulos D","year":"2022","unstructured":"Nikolopoulos D, Kitsos D, Papathanasiou M, et al.. Demyelinating syndromes in systemic lupus erythematosus: data from the \"Attikon\" Lupus Cohort. Front Neurol. 2022, 13:889613. 10.3389\/fneur.2022.889613","journal-title":"Front Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini A","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J, Vogrig A. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology. 2021, 96:754-66. 10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-023-00798-8","article-title":"Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review","volume":"21","author":"Horneff G","year":"2023","unstructured":"Horneff G, Minden K, Rolland C, Daly AC, Borlenghi C, Ruperto N. Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J. 2023, 21:20. 10.1186\/s12969-023-00798-8","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1550359","article-title":"Risks associated with use of TNF inhibitors in children with rheumatic diseases","volume":"15","author":"Marino A","year":"2019","unstructured":"Marino A, Giani T, Cimaz R. Risks associated with use of TNF inhibitors in children with rheumatic diseases. Expert Rev Clin Immunol. 2019, 15:189-98. 10.1080\/1744666X.2019.1550359","journal-title":"Expert Rev Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.957575","article-title":"Anti-NMDAR encephalitis in Crohn's disease undergoing long-term infliximab treatment: a case report","volume":"13","author":"Oh SJ","year":"2022","unstructured":"Oh SJ, Kwon YN, Lee CK, Lee JS. Anti-NMDAR encephalitis in Crohn's disease undergoing long-term infliximab treatment: a case report. Front Immunol. 2022, 13:957575. 10.3389\/fimmu.2022.957575","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok A","year":"2020","unstructured":"Kunchok A, Aksamit AJ Jr, Davis JM 3rd, et al.. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020, 77:937-46. 10.1001\/jamaneurol.2020.1162","journal-title":"JAMA Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000992","article-title":"Demyelinating events following initiation of anti-TNF\u03b1 therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis","volume":"8","author":"Taylor TR","year":"2021","unstructured":"Taylor TR, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating events following initiation of anti-TNF\u03b1 therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurol Neuroimmunol Neuroinflamm. 2021, 8:e992. 10.1212\/NXI.0000000000000992","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201472","article-title":"Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 Canadian provinces: a population-based study","volume":"100","author":"Li L","year":"2023","unstructured":"Li L, Avi\u00f1a-Zubieta JA, Bernstein CN, et al.. Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 Canadian provinces: a population-based study. Neurology. 2023, 100:e558-67. 10.1212\/WNL.0000000000201472","journal-title":"Neurology"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12997","article-title":"Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients","volume":"41","author":"De Felice KM","year":"2015","unstructured":"De Felice KM, Novotna M, Enders FT, Faubion WA, Tremaine WJ, Kantarci OH, Raffals LE. Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Aliment Pharmacol Ther. 2015, 41:99-107. 10.1111\/apt.12997","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12147","article-title":"Anti-TNF alpha medications and neuropathy","volume":"20","author":"Tsouni P","year":"2015","unstructured":"Tsouni P, Bill O, Truffert A, Liaudat C, Ochsner F, Steck AJ, Kuntzer T. Anti-TNF alpha medications and neuropathy. J Peripher Nerv Syst. 2015, 20:397-402. 10.1111\/jns.12147","journal-title":"J Peripher Nerv Syst"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.25000\/acem.870894","article-title":"Evaluation of peripheral nerves in patients receiving anti -TNF- \u03b1 drug therapy","volume":"6","author":"Ekinci B","year":"2021","unstructured":"Ekinci B, Ya\u015far H, Arslan YK. Evaluation of peripheral nerves in patients receiving anti -TNF- \u03b1 drug therapy. Arch Clin Exp Med. 2021, 6:88-91. 10.25000\/acem.870894","journal-title":"Arch Clin Exp Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002924","article-title":"Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers","volume":"9","author":"Delcoigne B","year":"2023","unstructured":"Delcoigne B, Kopp TI, Arkema EV, et al.. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. RMD Open. 2023, 9:e002924. 10.1136\/rmdopen-2022-002924","journal-title":"RMD Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp TI","year":"2020","unstructured":"Kopp TI, Delcoigne B, Arkema EV, et al.. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Ann Rheum Dis. 2020, 79:566-72. 10.1136\/annrheumdis-2019-216693","journal-title":"Ann Rheum Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.09.006","article-title":"Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases","volume":"48","author":"Etminan M","year":"2019","unstructured":"Etminan M, Sodhi M, Samii A, Carleton BC, Kezouh A, Antonio Avina-Zubieta J. Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. Semin Arthritis Rheum. 2019, 48:1083-6. 10.1016\/j.semarthrit.2018.09.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102942","article-title":"Use of anti-TNF-\u03b1 therapy in Crohn's disease is associated with increased incidence of multiple sclerosis","volume":"51","author":"Avasarala J","year":"2021","unstructured":"Avasarala J, Guduru Z, McLouth CJ, Wilburn A, Talbert J, Sutton P, Sokola BS. Use of anti-TNF-\u03b1 therapy in Crohn's disease is associated with increased incidence of multiple sclerosis. Mult Scler Relat Disord. 2021, 51:102942. 10.1016\/j.msard.2021.102942","journal-title":"Mult Scler Relat Disord"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/art.22056","article-title":"Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis","volume":"54","author":"Setoguchi S","year":"2006","unstructured":"Setoguchi S, Solomon DH, Weinblatt ME, et al.. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006, 54:2757-64. 10.1002\/art.22056","journal-title":"Arthritis Rheum"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111500","article-title":"Demyelinating events in rheumatoid arthritis after drug exposures","volume":"69","author":"Bernatsky S","year":"2010","unstructured":"Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis. 2010, 69:1691-3. 10.1136\/ard.2009.111500","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15318","article-title":"Demyelinating events following anti-tumor necrosis factor alpha therapy: rare but challenging to treat","volume":"29","author":"Kal\u00e9n E","year":"2022","unstructured":"Kal\u00e9n E, Piehl F, Andersson M. Demyelinating events following anti-tumor necrosis factor alpha therapy: rare but challenging to treat. Eur J Neurol. 2022, 29:2047-55. 10.1111\/ene.15318","journal-title":"Eur J Neurol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar N","year":"2019","unstructured":"Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler. 2019, 25:1079-85. 10.1177\/1352458519828601","journal-title":"Mult Scler"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12385","article-title":"Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System","volume":"38","author":"Deepak P","year":"2013","unstructured":"Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2013, 38:388-96. 10.1111\/apt.12385","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)","volume":"16","author":"P\u00e9rez-De-Lis M","year":"2017","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, Kostov B, Perez-Alvarez R, Brito-Zer\u00f3n P, Ramos-Casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf. 2017, 16:1255-71. 10.1080\/14740338.2017.1372421","journal-title":"Expert Opin Drug Saf"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60091409","article-title":"Neurological side effects of TNF-\u03b1 inhibitors revisited: a review of case reports","volume":"60","author":"Gogulescu A","year":"2024","unstructured":"Gogulescu A, Blidisel A, Soica C, et al.. Neurological side effects of TNF-\u03b1 inhibitors revisited: a review of case reports. Medicina (Kaunas). 2024, 60:1409. 10.3390\/medicina60091409","journal-title":"Medicina (Kaunas)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53658-8","article-title":"Molecular mimicry as a mechanism of viral immune evasion and autoimmunity","volume":"15","author":"Maguire C","year":"2024","unstructured":"Maguire C, Wang C, Ramasamy A, et al.. Molecular mimicry as a mechanism of viral immune evasion and autoimmunity. Nat Commun. 2024, 15:9403. 10.1038\/s41467-024-53658-8","journal-title":"Nat Commun"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory AP","year":"2012","unstructured":"Gregory AP, Dendrou CA, Attfield KE, et al.. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012, 488:508-11. 10.1038\/nature11307","journal-title":"Nature"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa144","article-title":"Demyelination after anti-TNF therapy: who is at risk?","volume":"14","author":"Williams I","year":"2020","unstructured":"Williams I, Uhlig HH. Demyelination after anti-TNF therapy: who is at risk?. J Crohns Colitis. 2020, 14:1651-2. 10.1093\/ecco-jcc\/jjaa144","journal-title":"J Crohns Colitis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.1","article-title":"Monoclonal antibody therapy-associated neurological disorders","volume":"7","author":"Bosch X","year":"2011","unstructured":"Bosch X, Saiz A, Ramos-Casals M. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011, 7:165-72. 10.1038\/nrneurol.2011.1","journal-title":"Nat Rev Neurol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.02.003","article-title":"Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents","volume":"32","author":"Atzeni F","year":"2018","unstructured":"Atzeni F, Talotta R, Masala IF, Gerardi MC, Casale R, Sarzi-Puttini P. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. Best Pract Res Clin Rheumatol. 2018, 32:500-10. 10.1016\/j.berh.2019.02.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103332","article-title":"Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders","volume":"22","author":"De Stefano L","year":"2023","unstructured":"De Stefano L, Pallavicini FB, Mauric E, Piccin V, Vismara EM, Montecucco C, Bugatti S. Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun Rev. 2023, 22:103332. 10.1016\/j.autrev.2023.103332","journal-title":"Autoimmun Rev"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098187","article-title":"Focus on anti-tumour necrosis factor (TNF)-\u03b1-related autoimmune diseases","volume":"24","author":"Lopetuso LR","year":"2023","unstructured":"Lopetuso LR, Cuomo C, Mignini I, Gasbarrini A, Papa A. Focus on anti-tumour necrosis factor (TNF)-\u03b1-related autoimmune diseases. Int J Mol Sci. 2023, 24:8187. 10.3390\/ijms24098187","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/ar4582","article-title":"Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study","volume":"16","author":"Kaltsonoudis E","year":"2014","unstructured":"Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014, 16:R125. 10.1186\/ar4582","journal-title":"Arthritis Res Ther"},{"key":"ref44","article-title":"Tumor necrosis factor-\u03b1 inhibitor use in psoriasis patients with a first-degree relative with multiple sclerosis","volume":"14","author":"Mansouri B","year":"2015","unstructured":"Mansouri B, Horner ME, Menter A. Tumor necrosis factor-\u03b1 inhibitor use in psoriasis patients with a first-degree relative with multiple sclerosis. J Drugs Dermatol. 2015, 14:876-8.","journal-title":"J Drugs Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.84.14_supplement.P4.067","article-title":"CNS demyelination during Anti TNF-alpha therapy","volume":"84","author":"Dahl K","year":"2015","unstructured":"Dahl K, Frederiksen Battisti JL. CNS demyelination during Anti TNF-alpha therapy. Neurology. 2015, 84:P4.067. 10.1212\/WNL.84.14_supplement.P4.067","journal-title":"Neurology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512965-systematic-review-and-meta-analysis-on-central-andor-peripheral-nervous-system-demyelination-in-patients-treated-with-tumor-necrosis-factor-alpha-tnf--inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:21:03Z","timestamp":1789150863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512965-systematic-review-and-meta-analysis-on-central-andor-peripheral-nervous-system-demyelination-in-patients-treated-with-tumor-necrosis-factor-alpha-tnf--inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.116108","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}